2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. PMID: 36282299, DOI: 10.1007/s00259-022-06002-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyTextbook outcomeInternal radiation therapyHepatocellular carcinomaRadiation therapyPatient-important outcomesLarge observational studiesNuclear medicine physiciansEntire intervention processRandomized trialsRoutine careResultsA totalObservational studyMultistep interventionMedicine physiciansInterventional radiologistsSenior authorClinical roundsCarcinomaTherapyInterventionOutcomesIntraarterial Therapies for the Management of Hepatocellular Carcinoma
Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers 2022, 14: 3351. PMID: 35884412, PMCID: PMC9322128, DOI: 10.3390/cancers14143351.Peer-Reviewed Original ResearchDrug-eluting bead transarterial chemoembolizationHepatic artery infusionHepatocellular carcinomaTransarterial therapiesTransarterial chemoembolizationImage-guided locoregional therapiesBead transarterial chemoembolizationCatheter-based treatmentManagement of patientsLocoregional therapyBland embolizationIntraarterial therapyRadioembolization therapyEmbolic agentTherapyChemoembolizationCarcinomaEmbolizationPatientsArteryReviewInfusionTumorsTranslating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma
Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma. Journal Of Hepatology 2022, 77: 6-8. PMID: 35417743, DOI: 10.1016/j.jhep.2022.03.035.Peer-Reviewed Original Research
2021
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinomaDeep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2020
Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesions
2018
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma.
Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma. Journal Of Visualized Experiments 2018 PMID: 30371657, PMCID: PMC6235502, DOI: 10.3791/58382.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyN patientsHepatocellular carcinomaTrans-arterial therapiesIntra-arterial treatmentCohort of patientsStandard of careLikelihood of responseClinical research questionsSurgical resectionNew patientsTreatment responseUnivariate associationsPatientsTraining patientsInterventional radiologyTherapyCarcinomaTreatmentImage-guided therapyOutcomesFinal modelImaging dataResectionResponse
2017
The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging 2017, 46: 1-7. PMID: 28668723, PMCID: PMC5720941, DOI: 10.1016/j.clinimag.2017.05.007.Peer-Reviewed Original ResearchConceptsEarly response assessmentTransarterial chemoembolizationImaging-based criteriaResponse assessmentHepatocellular carcinomaTumor response assessmentAnti-angiogenic therapyQuantitative European AssociationTherapy armOverall survivalLiver criteriaAntiangiogenic therapyTreatment groupsPatientsSimilar associationEuropean AssociationBevacizumabChemoembolizationCarcinomaTherapyAssociationAssessmentFollowCriteriaBaseline
2016
Interventional Oncology in Hepatocellular Carcinoma
Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma. The Cancer Journal 2016, 22: 365-372. PMID: 27870678, PMCID: PMC5125535, DOI: 10.1097/ppo.0000000000000227.Peer-Reviewed Original ResearchConceptsInterventional oncologyLocoregional therapyHepatocellular carcinomaInterdisciplinary clinical practiceTumor response assessmentOngoing clinical trialsComplex clinical problemImmune response pathwaysTransarterial chemoembolizationCancer careCombination therapyClinical managementClinical trialsRadiofrequency ablationResponse assessmentSystemic effectsClinical problemClinical practiceEmbolic materialTherapyCancer treatmentIntraprocedural imagingOncologyRadiation oncologyCarcinomaSorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma.
Geschwind JH, Chapiro J. Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Gastroenterology & Hepatology 2016, 12: 504-506. PMID: 27917085, PMCID: PMC5114496.Peer-Reviewed Original ResearchSorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF, Chapiro J. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Clinical Advances In Hematology And Oncology 2016, 14: 585-7. PMID: 27487101.Peer-Reviewed Original Research
2015
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions
Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal Of Radiology 2015, 88: 20140564. PMID: 25978585, PMCID: PMC4651391, DOI: 10.1259/bjr.20140564.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyDiffusion of InnovationEmbolization, TherapeuticFemaleForecastingHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMicrospheresNiacinamidePatient SelectionPhenylurea CompoundsRadiopharmaceuticalsSorafenibYttrium RadioisotopesConceptsIntra-arterial therapyHepatocellular carcinomaSecondary liver malignanciesManagement of patientsHealthy liver tissueLocoregional therapyLiver malignanciesClinical rationaleHigh doseInterventional oncologySystematic reviewAnticancer treatmentLiver tissueInvasive natureClinical achievementsChemoresistant cancersTherapyMedical communityPatientsCarcinomaTreatmentPivotal roleMalignancySorafenibCancer